FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942300703> ?p ?o ?g. }

• W2942300703 endingPage "68" @default.
• W2942300703 startingPage "64" @default.
• W2942300703 abstract "Aims Despite widespread use of dual antiplatelet therapy in acute myocardial infarction, there remains a residual risk of morbidity and mortality. Bruton's Tyrosine Kinase inhibitors have been found to inhibit platelet aggregation through the Glycoprotein VI collagen-mediated pathway. The Bruton's Tyrosine Kinase inhibitor, Ibrutinib is used in the management of haematological malignancies and another Bruton's Tyrosine Kinase inhibitor, ONO-4059 (also known as tirabrutinib), is in clinical development. This is an observational study to evaluate the effects of Ibrutinib and ONO-4059 on platelet aggregation after acute myocardial infarction. Methods and results Twenty patients with a confirmed diagnosis of acute myocardial infarction were enrolled and blood samples obtained within 48 h of hospital admission. All patients were on dual antiplatelet therapy; aspirin plus a P2Y12 inhibitor (clopidogrel or ticagrelor). Blood samples were treated ex vivo with increasing concentrations of Ibrutinib (0, 0.5, 1, 2 μM) and ONO-4059 (0, 0.2, 0.5, 1 μM). Platelet aggregation was measured in response to collagen using a Multiplate analyser to estimate the area under the curve, with lower values indicating lower platelet aggregation. The median age was 63 years and 80% were male. The median area under the curve values for Ibrutinib concentrations 0 (control), 0.5, 1 and 2 μM were 18.5, 8 (P = 0.0004), 4.5 (P < 0.0001) and 2 (P < 0.0001) units and for ONO-4059 concentrations 0 (control), 0.2, 0.5 and1μM, median area under the curve values were 13, 12 (P = 0.7), 6.5 (P = 0.0001) and 5.5 (P = 0.0004 compared to control). Conclusion The Bruton's Tyrosine Kinase inhibitors, Ibrutinib and ONO-4059, show further inhibition of platelet aggregation in blood samples from patients with acute myocardial infarction, receiving dual antiplatelet therapy in a dose dependent manner. These results provide a rationale for Bruton's Tyrosine Kinase inhibitors to be tested as a potential new antiplatelet strategy for acute myocardial infarction." @default.
• W2942300703 created "2019-05-03" @default.
• W2942300703 creator A5009505831 @default.
• W2942300703 creator A5027193172 @default.
• W2942300703 creator A5035157909 @default.
• W2942300703 creator A5035754155 @default.
• W2942300703 creator A5037858868 @default.
• W2942300703 creator A5051370528 @default.
• W2942300703 creator A5074010901 @default.
• W2942300703 creator A5074207923 @default.
• W2942300703 creator A5090714953 @default.
• W2942300703 date "2019-07-01" @default.
• W2942300703 modified "2023-09-27" @default.
• W2942300703 title "Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction" @default.
• W2942300703 cites W1493000949 @default.
• W2942300703 cites W1553345686 @default.
• W2942300703 cites W1829587101 @default.
• W2942300703 cites W1976225087 @default.
• W2942300703 cites W1979834961 @default.
• W2942300703 cites W1986924929 @default.
• W2942300703 cites W1990906644 @default.
• W2942300703 cites W2011960630 @default.
• W2942300703 cites W2025707347 @default.
• W2942300703 cites W2049595552 @default.
• W2942300703 cites W2054220445 @default.
• W2942300703 cites W2058932848 @default.
• W2942300703 cites W2063262989 @default.
• W2942300703 cites W2082776243 @default.
• W2942300703 cites W2108206643 @default.
• W2942300703 cites W2114995492 @default.
• W2942300703 cites W2129425642 @default.
• W2942300703 cites W2129958400 @default.
• W2942300703 cites W2140501627 @default.
• W2942300703 cites W2141051634 @default.
• W2942300703 cites W2143032169 @default.
• W2942300703 cites W2165122118 @default.
• W2942300703 cites W2169387542 @default.
• W2942300703 cites W2171771895 @default.
• W2942300703 cites W2190884983 @default.
• W2942300703 cites W2191219754 @default.
• W2942300703 cites W2233614027 @default.
• W2942300703 cites W2237058775 @default.
• W2942300703 cites W2605172177 @default.
• W2942300703 cites W2613723809 @default.
• W2942300703 cites W2767685521 @default.
• W2942300703 cites W2794058157 @default.
• W2942300703 cites W2883175618 @default.
• W2942300703 cites W59149074 @default.
• W2942300703 cites W4210733855 @default.
• W2942300703 doi "https://doi.org/10.1016/j.thromres.2019.04.024" @default.
• W2942300703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31082751" @default.
• W2942300703 hasPublicationYear "2019" @default.
• W2942300703 type Work @default.
• W2942300703 sameAs 2942300703 @default.
• W2942300703 citedByCount "6" @default.
• W2942300703 countsByYear W29423007032020 @default.
• W2942300703 countsByYear W29423007032021 @default.
• W2942300703 countsByYear W29423007032022 @default.
• W2942300703 crossrefType "journal-article" @default.
• W2942300703 hasAuthorship W2942300703A5009505831 @default.
• W2942300703 hasAuthorship W2942300703A5027193172 @default.
• W2942300703 hasAuthorship W2942300703A5035157909 @default.
• W2942300703 hasAuthorship W2942300703A5035754155 @default.
• W2942300703 hasAuthorship W2942300703A5037858868 @default.
• W2942300703 hasAuthorship W2942300703A5051370528 @default.
• W2942300703 hasAuthorship W2942300703A5074010901 @default.
• W2942300703 hasAuthorship W2942300703A5074207923 @default.
• W2942300703 hasAuthorship W2942300703A5090714953 @default.
• W2942300703 hasBestOaLocation W29423007032 @default.
• W2942300703 hasConcept C126322002 @default.
• W2942300703 hasConcept C164705383 @default.
• W2942300703 hasConcept C170493617 @default.
• W2942300703 hasConcept C2777628954 @default.
• W2942300703 hasConcept C2777849778 @default.
• W2942300703 hasConcept C2777938653 @default.
• W2942300703 hasConcept C2778461978 @default.
• W2942300703 hasConcept C2779878957 @default.
• W2942300703 hasConcept C2780890252 @default.
• W2942300703 hasConcept C42362537 @default.
• W2942300703 hasConcept C500558357 @default.
• W2942300703 hasConcept C71924100 @default.
• W2942300703 hasConcept C89560881 @default.
• W2942300703 hasConcept C90059517 @default.
• W2942300703 hasConcept C90924648 @default.
• W2942300703 hasConcept C98274493 @default.
• W2942300703 hasConceptScore W2942300703C126322002 @default.
• W2942300703 hasConceptScore W2942300703C164705383 @default.
• W2942300703 hasConceptScore W2942300703C170493617 @default.
• W2942300703 hasConceptScore W2942300703C2777628954 @default.
• W2942300703 hasConceptScore W2942300703C2777849778 @default.
• W2942300703 hasConceptScore W2942300703C2777938653 @default.
• W2942300703 hasConceptScore W2942300703C2778461978 @default.
• W2942300703 hasConceptScore W2942300703C2779878957 @default.
• W2942300703 hasConceptScore W2942300703C2780890252 @default.
• W2942300703 hasConceptScore W2942300703C42362537 @default.
• W2942300703 hasConceptScore W2942300703C500558357 @default.
• W2942300703 hasConceptScore W2942300703C71924100 @default.
• W2942300703 hasConceptScore W2942300703C89560881 @default.

• next